You are here

  • Home
  • Archive
  • Volume 10, Issue 3
  • Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy

Article metrics

Article menu

Download PDFPDF

Review
Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy

 

Online download statistics by month:

Online download statistics by month: March 2022 to July 2025

AbstractFullPdf
Mar 202251052084
Apr 2022502514111
May 202235837061
Jun 202225627155
Jul 202219821046
Aug 2022200213131
Sep 202223724893
Oct 202227229098
Nov 202223324094
Dec 202218719059
Jan 202315215649
Feb 202316116262
Mar 202314915480
Apr 202311111659
May 202312712860
Jun 202312812965
Jul 202312513453
Aug 202313814365
Sep 202310710736
Oct 202311711946
Nov 202312112231
Dec 2023909344
Jan 2024777951
Feb 202412012240
Mar 202417117466
Apr 202413514057
May 202410010151
Jun 20249710049
Jul 202410711141
Aug 2024717331
Sep 2024687028
Oct 202412212543
Nov 202411511640
Dec 202413513635
Jan 202511811944
Feb 202531431494
Mar 202513713765
Apr 202518018348
May 202511411455
Jun 2025868933
Jul 2025110
Total674769332353